Next Article in Journal
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
Next Article in Special Issue
Benchmarking Time-to-Treatment Initiation in Sarcoma Care Using Real-World-Time Data
Previous Article in Journal
Modulation of the Tumor Microenvironment by Ellagic Acid in Rat Model for Hepatocellular Carcinoma: A Potential Target against Hepatic Cancer Stem Cells
Previous Article in Special Issue
Unlocking the Power of Benchmarking: Real-World-Time Data Analysis for Enhanced Sarcoma Patient Outcomes
 
 
Article

Article Versions Notes

Cancers 2023, 15(19), 4892; https://doi.org/10.3390/cancers15194892
Action Date Notes Link
article xml file uploaded 9 October 2023 10:04 CEST Original file -
article xml uploaded. 9 October 2023 10:04 CEST Update https://www.mdpi.com/2072-6694/15/19/4892/xml
article pdf uploaded. 9 October 2023 10:04 CEST Version of Record https://www.mdpi.com/2072-6694/15/19/4892/pdf
article html file updated 9 October 2023 10:05 CEST Original file https://www.mdpi.com/2072-6694/15/19/4892/html
Back to TopTop